Posts tagged Jason Kolbert
Maxim downgrades Pluristem to hold

Maxim Group downgraded Pluristem Therapeutics (NASDAQ:PSTI) to “hold” from “buy” and eliminated its price target, saying it is not in agreement with the company in terms of its clinical plans. The stock closed at $1.14 on Feb. 13.

Read More
Maxim upgrades ADMA Biologics to buy

Maxim Group upgraded ADMA Biologics (NASDAQ:ADMA) to ‘buy” from “hold” and established a price target of $13 after the company agreed to acquire Biotest Pharmaceuticals’ immunoglobulin manufacturing facility in Florida. The stock was quoted at $5.54 in afternoon trading on Jan. 24.

Read More
Maxim upgrades Keryx to buy

Maxim Group upgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “buy” from “hold” and reinstated its $7 price target after the FDA approved its application for a second contract manufacturer of Auryxia for the control of serum phosphorus levels in patients with CKD on dialysis.

Shares of Keryx were changing hands at $5.35, up 56 cents, in afternoon trading on Wednesday.

Read More
Maxim cuts Omeros price target to $19

Maxim Group lowered its price target for Omeros (NASDAQ:OMER) to $19 from $30, citing a higher risk value from its three valuation models. The stock closed at $13.38 on Tuesday.

Read More
Maxim ups Sophiris price target to $6

Maxim Group raised it price target for Sophiris Bio (NASDAQ:SPHS) to $6 from $4, citing better data of the company’s topsalysin drug candidate. The stock closed at $5.04 on Tuesday.

Read More
Maxim cuts Sucampo Pharma price target to $17

Maxim Group lowered its price target for Sucampo Pharmaceuticals (NASDAQ:SCMP) to $17 from $26, citing a combination of the market environment and an assessment of the catalysts and risks. The stock was quoted at $11.89 at afternoon trading on Monday.

Analyst Jason Kolbert writes that he expects Sucampo’s stock to be driven by the quarterly sales progress associated with Amitiza, integration progress with RJ Ueno (Japan), and future product acquisitions.

Read More
Maxim cuts Galmed Pharma price target to $9

Maxim Group lowered its price target for Galmed Pharmaceuticals (NASDAQ:GLMD) to $9 from $24, citing a bearish biotech market environment, catalysts, and revisions to timelines, as well as other related assumptions. The stock was changing hands at $4.26 in Monday afternoon trading.

Analyst Jason Kolbert writes that the next major inflection point for Galmed is proof-of-concept data for Aramchol in nonalcoholic steatohepatitis (NASH) in 2018.

Read More
Maxim downgrades Keryx Biopharmaceuticals to hold

Maxim Group downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target for the stock, which was quoted at $5.16, down $2.20, or 30% in trading Monday afternoon.

The move reflected news that Keryx will now face a manufacturing disruption for at least one quarter and possibly more, writes analyst Jason Kolbert.

Read More
Maxim likes ContraVir merger with Ciclofilin

The merger of ContraVir Pharmaceuticals (NASDAQ:CTRV) with closely-held Ciclofilin Pharmaceuticals strengthens ContraVir’s position in the hepatitis B virus (HBV) space, according to a new report from Maxim Group analyst Jason Kolbert.

The mechanism of action of Ciclofilin’s antiviral asset, CPI-431-32, should be complementary to ContraVir’s CMX157 by inhibiting distinct critical steps in the viral life cycle, he said.

Read More
Maxim starts ContraVir Pharma at buy

Maxim Group has initiated coverage of ContraVir Pharmaceuticals (NASDAQ:CTRV) with a “buy” rating and price target of $4, calling the company an emerging anti-viral leader with two clean shots on goal. The stock closed at 97 cents on Thursday.

“ContraVir has two programs: one in shingles (Phase 3) and one in hepatitis B (Phase 1/2), both of which can be value drivers for the company,” writes analyst Jason Kolbert.

Read More